Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy, originally developed to treat certain types of cancers. Today this therapy is being trialed in numerous studies to treat autoimmune diseases, including myasthenia gravis.
The long-running Descartes-08 trial is now in phase 3 (AURORA), with its first participant enrolled last May. It targets BCMA and uses RNA instead of DNA, which does not require pre-treatment chemotherapy and can be administered in an outpatient setting, according to a company press release from Cartesian Therapeutics, Inc.
- Learn more about phase 2b trial results and about the ongoing phase 3 trial in this MGFA webinar.
Another BCMA trial underway is a phase 1 study from Arcellx, Inc. looking at patients with non-oncology plasma cell-related disease.
- Learn more about this trial, which is currently recruiting, in this MGFA webinar.
A more MG-specific study called Reset MG, sponsored by Cabaletta Bio, is actively recruiting patients. This phase 1/2 trial is evaluating the safety and efficacy of a treatment called CABA-201.
- Learn more about this treatment and trial in this MGFA webinar.
In October, Kyverna Therapeutics reported positive interim data from its phase 2 clinical trial of KYV-101, another CAR T-cell therapy being tested for MG. “Patients experienced rapid and unprecedented symptom improvement without the need for ongoing background therapy,” said the company’s CEO in a press release. The results reinforce the company’s confidence in its phase 3 trial design.
- Learn more about the mechanism of action in this therapy and the clinical trial in this MGFA webinar.
For more information on CAR T-cell therapy trials for myasthenia gravis, visit clinicaltrials.gov and type in myasthenia gravis CAR T-cell therapy.
– Article by Mary Bolster